Navigation Links
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
Date:6/13/2008

and director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas Medical Center in Kansas City. "Requip XL provides continuous delivery of ropinirole over 24 hours to provide smoother blood levels without the peaks and troughs that multiple daily doses typically deliver. It is an important once-daily treatment option for patients with Parkinson's disease."

Requip XL is an extended-release, once-daily tablet formulation that uses SkyePharma PLC's (LSE: SKP) patented GEOMATRIX(TM) technology. This innovative tri-layer formulation allows for continuous delivery of ropinirole over 24 hours to provide smooth blood levels. Requip XL offers physicians and patients a simple titration regimen; it also offers a convenient, once-daily dosing schedule compared to other oral dopamine agonists, which are dosed multiple times a day.

Clinical Study

FDA approval was based primarily on results from the EASE-PD (Efficacy And Safety Evaluation in Parkinson Disease) Adjunct Study, a multi-center, double-blind, placebo-controlled study conducted in patients with idiopathic Parkinson's disease not adequately controlled with l-dopa. A total of 393 patients in the study were randomized to receive either Requip XL (n=202) or placebo (n=191) once daily for 24 weeks in addition to l-dopa. The study's primary endpoint was the mean change from baseline at week 24 in awake time spent "off," which was measured via patient diaries. Results from the study showed that Requip XL significantly reduced "off" time by an average of 2.1 hours per day from baseline, compared to a reduction of 0.4 hours per day for placebo.

Once-daily use of Requip XL was generally well tolerated in the study. The withdrawal rate due to adverse reactions was low and similar between groups (6 percent Requip XL vs. 5 percent placebo). The most common adverse reactions reported in patients taking Requip XL compared to placebo were dyskinesia (13 percent vs. 3 percent),
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
2. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
3. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... and NINGBO, China , ... the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced ... development of generic pharmaceuticals, primarily targeting the ... the agreement, Amerigen and Menovo will jointly develop products ... States . Menovo will be responsible for manufacturing ...
(Date:8/27/2014)... Aug. 27, 2014 Ambit Biosciences (Nasdaq: AMBI ... drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, ... Care Conference to be held at The New York Palace ... September 3-4, 2014. Alan Fuhrman , Ambit,s ... lead drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
(Date:8/27/2014)... FL (PRWEB) August 27, 2014 The ... September 5th, 6th and 7th at the Florida State ... Festival celebrates all Latino art and cultures from around ... present their platinum sponsor Go Smart Mobile and Univision ... Action Festival is expecting an estimate of 4,000 people ...
(Date:8/27/2014)... Dennis Thompson HealthDay Reporter ... who has been mugged in a dark alley will likely ... a fear of being attacked. But neuroscientists working with ... memories are linked with positive and negative emotions. And in ... attached to a memory. In essence, they made once-reluctant ...
(Date:8/27/2014)... 28, 2014 BRIC Laparoscopes Market Outlook ... provides key market data on the BRIC Laparoscopes market. ... volume (in units) and average prices (in US dollars) ... and Flexible Tip Video Laparoscopes), Robotic Surgical Systems and ... of advantages to the patient with laparoscopic surgery versus ...
(Date:8/27/2014)... Dr. Stewart Shofner and Dr. Kevin ... suffering from impaired vision. Some of the most common ... . Recently, Dr. Shofner has noticed a significant increase ... and also online. To help patients understand the facts, ... , 1)    Myth: People with perfect vision won’t develop glaucoma. ...
(Date:8/27/2014)... August 27, 2014 The extensive ... nurses by healthcare research group Black Book Rankings ... not adequately staffed, supplied or built to care ... Book initiated this annual survey to gain stakeholder ... infection control, epidemiology and emergency preparedness systems,” said ...
Breaking Medicine News(10 mins):Health News:Marc Anthony to Perform at "Nieves Productions" Latinos in Action Festival 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 2Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 3Health News:American Hospitals Are Vastly Unprepared for Ebola Patients, Reveals Black Book™ Survey of Emergency Physicians, Nurses and Infection Control Practitioners 4
... ... in technology will have a bottom-line impact on people’s health. While ... is a new breed of technology aimed at preventative, integrative health solutions. ... tracking tools, providing members ways to track, understand, and improve their health ...
... , Jan. 19 The National Theatre for Children ... with the only global entertainment brand dedicated to kids health, ... healthy exercise to the kids and families who need it most. ... will tour a curriculum-based and interactive live show – performed by ...
... Birth Defect Research Reveals Craniofacial & Brain ... CELEBRATION, Fla. , Jan. 19 Nearly two-thirds of ... Birth Defect Registry (NBDR) also suffer from structural birth defects, ... . The group reported that most of the defects affect the ...
... acids in the solution reduce inflammation, researchers note , ... to intravenous solutions proved beneficial for intensive care patients ... a new study finds. , The study, published Jan. ... 13 patients who received fish oil in the normal ...
... ... Screening and Treatment , ... Heights, NJ (Vocus) January 19, 2010 -- During Glaucoma Awareness Month, Summit Medical Group wants ... the eyes that causes vision loss. Because there often are no symptoms in its early ...
... ... satisfied with their health insurers, according to a study released today by ... employers of all sizes are taking a critical look at their health ... looking to their health plan providers for information, technology and strategies to ...
Cached Medicine News:Health News:Online Tools to Transform the Way People Manage Their Health 2Health News:Online Tools to Transform the Way People Manage Their Health 3Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 2Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 3Health News:World's #1 Health Brand for Kids Joins Forces With World's #1 In-School Children's Theatre 4Health News:High Rates of Birth Defects Found in Autistic Children 2Health News:Adding Fish Oil to IV May Speed Sepsis Recovery 2Health News:January is Glaucoma Awareness Month 2Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 2Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 3Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 4Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 5Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 6Health News:Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study 7
... head design has been carefully considered with both ... head ensures the optimum viewing angle and the ... laser aligned for perfect focus where it is ... paper. This along with Keeler's wide angle ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
... 200S is the first hand-held ... of patented aspherical optics (U.S. ... of corrective lenses from 36 ... diopter steps. A perfectly-focused image ...
... The ophthalmoscope with superior aspherical optics. ... illumination and observation beam by means of ... iris reflex (Gullstrand-principle). The Beta 200 allows ... illuminated section of the retina even with ...
Medicine Products: